Description of use

Vara AI supports breast cancer screening and diagnostic mammography across both 2D and 3D imaging. It returns a classification compatible with BI-RADS, a suspiciousness score, a density assessment, CAD lesion markers, and a comprehensive AI report, with industry-leading analysis of up to 3 priors across multiple screening rounds. In the PRAIM prospective study (largest prospective study globally, Nature Medicine 2025, n=461,818, 12 sites, 119 radiologists), AI-supported double reading increased cancer detection by +17.6% while maintaining non-inferior recall. Vara is deployed across >50% of Germany's organized national screening programme - running on all major scanner types with no exclusion criteria - and is one of the few only breast imaging AI certified Class IIb for independent reading. Vara is CE-certified for DBT, with CE approval for risk prediction expected later in 2026.